A meta-analysis of the performance characteristics of the free prostate-specific antigen test

Urology

Volumn 67, Issue 4, 2006, Pages 762-768

  Lee, Richard ^a   Localio, A Russell ^b,c   Armstrong, Katrina ^b,d   Malkowicz, S Bruce ^b,c   Schwartz, J Sanford ^b,c,d  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER DIAGNOSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; HISTOPATHOLOGY; HUMAN; MALE; MAXIMUM LIKELIHOOD METHOD; MEDICAL DECISION MAKING; MEDICAL LITERATURE; MEDICAL RESEARCH; MEDLINE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; ROC CURVE; SENSITIVITY AND SPECIFICITY;

BLOOD CHEMICAL ANALYSIS; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY;

EID: 33646009994     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2005.10.052     Document Type: Article

References (61)

1. Catalona W.J., Richie J.P., Ahmann F.R., et al. Comparison of digital rectal examination and serum prostate-specific antigen in the early detection of prostate cancer. results of a multicenter clinical trial of 6,630 men. J Urol 151: (1994) 1283-1290
2. Stenman U.H., Leinonen J., Alfthan H., et al. A complex between prostate-specific antigen and alpha-1-chymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer. assay of the complex improves clinical sensitivity for cancer. Cancer Res 51: (1991) 222-226
3. Christensson A., Bjork T., Nilsson O., et al. Serum prostate specific antigen complexed to alpha-1-chymotrypsin as an indicator of prostate cancer. J Urol 150 (1993) 100-105
4. Catalona W.J., Partin A.W., Slawin K.M., et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease. a prospective multicenter clinical trial. JAMA 279 (1998) 1542-1547
5. Junker R., Brandt B., Zechel C., et al. Comparison of prostate-specific antigen (PSA) measured by four combinations of free PSA and total PSA assays. Clin Chem 43 (1997) 1588-1594
6. Irwig L., Macaskill P., Glasziou P., et al. Meta-analytic methods for diagnostic test accuracy. J Clin Epidemiol 48 (1995) 119-130
7. Agresti A. Categorical Data Analysis. 2nd ed (2002), John Wiley & Sons, New York pp 471-472
8. Daly L.E. Confidence limits made easy. interval estimation using a substitution method. Am J Epidemiol 147 (1998) 783-790
9. Delong E.R., DeLong D.M., and Clarke-Pearson D.L. Comparing the area under two or more correlated receiver operating curves. a nonparametric approach. Biometrics 44 (1988) 836-845
10. Woodrum D., and York L. Two-year stability of free and total PSA in frozen serum samples. Urology 52 (1998) 247-251
11. Carter H.B., Partin A.W., Luderer A.A., et al. Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis. Urology 49 (1997) 379-384
12. Pannek J., Rittenhouse H.G., Chan D.W., et al. The use of percent free prostate specific antigen for staging clinically localized prostate cancer. J Urol 159 (1998) 1238-1242
13. Gann P.H., Ma J., Catalona W.J., et al. Strategies combining total and percent free prostate specific antigen for detecting prostate cancer. a prospective evaluation. J Urol 167 (2002) 2427-2434
14. Okihara K., Cheli C.D., Partin A.W., et al. Comparative analysis of complexed prostate specific antigen, free prostate specific antigen, and their ratio in detecting prostate cancer. J Urol 167 (2002) 2017-2023
15. Vashi A.R., Wojno K.J., Henricks W., et al. Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system. Urology 49 (1997) 19-27
16. Brawer M.K., Cheli C.D., Neaman I.E., et al. Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer. J Urol 163: (2000) 1476-1480
17. Stamey T.A., and Yemoto C.E. Examination of the 3 molecular forms of serum prostate specific antigen for distinguishing negative from positive biopsy. relationship to transition zone volume. J Urol 163 (2000) 119-126
18. Goddard C.C., Gilbert F.J., Needham G., et al. Routine receiver operating characteristic analysis in mammography as a measure of radiologists' performance. Br J Radiol 71 (1998) 1012-1017
19. Stoutjesdijk M.J., Boetes C., Jager G.J., et al. Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer. J Natl Cancer Inst 93 (2001) 1095-1102
20. Markopoulos C., Kouskos E., Koufopoulos K., et al. Use of artificial neural networks (computer analysis) in the diagnosis of microcalcifications on mammography. Eur J Radiol 39 (2001) 60-65
21. f after radical prostatectomy. J Urol 155 suppl (1996) 416A
22. Akdas A., Cevik I., and Tarcan T. The role of free prostate-specific antigen in the diagnosis of prostate cancer. Br J Urol 79: (1997) 920-923
23. Bjork T., Piironen T., and Pettersson K. Comparison of analysis of the different prostate-specific antigen forms in serum for detection of clinically localized prostate cancer. Urology 48: (1996) 882-888
24. Carlson G.D., Calvanese C.B., and Partin A.W. An algorithm combining age, total prostate-specific antigen (PSA), and percent free PSA to predict prostate cancer. results on 4298 cases. Urology 52: (1998) 455-461
25. Catalona W.J., Smith D.S., and Wolfert R.L. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 274: (1995) 1214-1220
26. Catalona W.J., Partin A.W., and Finlay J.A. Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/ml and digital rectal examination is not suspicious for prostate cancer. an alternative model. Urology 54: (1999) 220-224
27. Chen Y.T., Luderer A.A., and Thiel R.P. Using proportions of free to total prostate-specific antigen, age, and total prostate-specific antigen to predict the probability of prostate cancer. Urology 47: (1996) 518-524
28. Demura T., Shinohara N., and Tanaka M. The proportion of free to total prostate specific antigen. a method of detecting prostate carcinoma. Cancer 77: (1996) 1137-1143
29. Djavan B., Zlotta A.R., and Byttebier G. Prostate specific antigen density of the transition zone for early detection of prostate cancer. J Urol 160: (1998) 411-418
30. Egawa S., Soh S., and Ohori M. The ratio of free to total serum prostate specific antigen and its use in differential diagnosis of prostate carcinoma in Japan. Cancer 79: (1997) 90-98
31. Espana F., Royo M., and Martinez M. Free and complexed prostate specific antigen in the differentiation of benign prostatic hyperplasia and prostate cancer. studies in serum and plasma samples. J Urol 160 6 Pt 1 (1998) 2081-2088
32. Filella X., Alcover J., and Molina R. Clinical evaluation of free PSA/total PSA (prostate-specific antigen) ratio in the diagnosis of prostate cancer. Eur J Cancer 33: (1997) 1226-1229
33. Filella X., Alcover J., and Molina R. Clinical usefulness of free PSA fraction as an indicator of prostate cancer. Int J Cancer 63: (1995) 780-784
34. Filella X., Alcover J., and Quinto L. Evaluation of a multivariate prostate-specific antigen and percentage of free prostate-specific antigen logistic regression model in the diagnosis of prostate cancer. Tumour Biology 20: (1999) 312-318
35. Gion M., Mione R., and Barioli P. Percent free prostate-specific antigen in assessing the probability of prostate cancer under optimal analytical conditions. Clin Chem 44: (1998) 2462-2470
36. Higashihara E., Nutahara K., and Kojima M. Significance of free prostate-specific antigen and gamma-seminoprotein in the screening of prostate cancer. Prostate Suppl 7: (1996) 40-47
37. Jung K., Meyer A., and Lein M. Ratio of free-to-total prostate specific antigen in serum cannot distinguish patients with prostate cancer from those with chronic inflammation of the prostate. J Urol 159: (1998) 1595-1598
38. Kuriyama M., Kawada Y., and Arai Y. Significance of free to total PSA ratio in men with slightly elevated serum PSA levels. a cooperative study. Jpn J Clin Oncol 28: (1998) 661-665
39. Kwiatkowski M.K., Recker F., and Piironen T. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL. Urology 52: (1998) 360-365
40. Letran J.L., Blase A.B., and Loberiza F.R. Repeat ultrasound guided prostate needle biopsy. use of free-to-total prostate specific antigen ratio in predicting prostatic carcinoma. J Urol 160: (1998) 426-429
41. Li W., Ren Y., and Mee V. Prostate-specific antigen ratio correlates with aggressiveness of histology grades of prostate cancer. Clin Biochem 32: (1999) 31-37
42. Lodding P., Aus G., and Bergdahl S. Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3 to 4 ng./ml prostate specific antigen. J Urol 159: (1998) 899-903
43. Luderer A.A., Chen Y.T., and Soriano T.F. Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. Urology 46: (1995) 187-194
44. Maeda H., Arai Y., and Aoki Y. Complexed prostate-specific antigen and its volume indexes in the detection of prostate cancer. Urology 54: (1999) 225-228
45. Masters J.G., Keegan P.E., and Hildreth A.J. Free/total serum prostate-specific antigen ratio. how helpful is it in detecting prostate cancer?. Brit J Urol 81: (1998) 419-423
46. Mettlin C., Chesley A.E., and Murphy G.P. Association of free PSA percent, total PSA, age, and gland volume in the detection of prostate cancer. Prostate 39: (1999) 153-158
47. Meyer A., Jung K., and Lein M. Factors influencing the ratio of free to total prostate-specific antigen in serum. Int J Cancer 74: (1997) 630-636
48. Mione R., Barioli P., and Barichello M. Prostate cancer probability after total PSA and percent free PSA determination. Int J Biol Markers 13: (1998) 77-86
49. Mione R., Aimo G., and Bombardieri E. Preliminary results of clinical evaluation of the free/total prostate-specific antigen ratio in a multicentric study. Tumori 82: (1996) 543-549
50. Morgan T.O., McLeod D.G., and Leifer E.S. Prospective use of free prostate-specific antigen to avoid repeat prostate biopsies in men with elevated total prostate-specific antigen. Urology 48 suppl 6A (1996) 76-80
51. Morote J., Raventos C.X., and Lorente J.A. Comparison of percent free prostate specific antigen and prostate specific antigen density as methods to enhance prostate specific antigen specificity in early prostate cancer detection in men with normal rectal examination and prostate specific antigen between 4.1 and 10 ng./ml. J Urol 158: (1997) 502-504
52. Partin A.W., Catalona W.J., and Southwick P.C. Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection. influence of total PSA, prostate volume, and age. Urology 48 suppl 6A (1996) 55-61
53. Pearson J.D., Luderer A.A., and Metter E.J. Longitudinal analysis of serial measurements of free and total PSA among men with and without prostatic cancer. Urology 48 suppl 6A (1996) 4-9
54. Prestigiacomo A.F., Lilja H., and Pettersson K. A comparison of the free fraction of serum prostate specific antigen in men with benign and cancerous prostates. the best case scenario. J Urol 156 2 Pt 1 (1996) 350-354
55. Prestigiacomo A.F., and Stamey T.A. Can free and total prostate specific antigen and prostatic volume distinguish between men with negative and positive systematic ultrasound guided prostate biopsies?. J Urol 157: (1997) 189-194
56. Recker F., Kwiatkowski M.K., and Piironen T. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma. Cancer 83: (1998) 2540-2547
57. Thiel R.P., Oesterling J.E., and Wojno K.J. Multicenter comparison of the diagnostic performance of free prostate-specific antigen. Urology 48 suppl 6A (1996) 45-50
58. Tornblom M., Norming U., and Adolfsson J. Diagnostic value of percent free prostate-specific antigen. retrospective analysis of a population-based screening study with emphasis on men with PSA levels less than 3.0 ng/mL. Urology 53: (1999) 945-950
59. Toubert M.E., Guillet J., and Chiron M. Percentage of free serum prostate-specific antigen. a new tool in the early diagnosis of prostatic cancer. Eur J Cancer 32A (1996) 2088-2093
60. Veltri R.W., and Miller M.C. Free/total PSA ratio improves differentiation of benign and malignant disease of the prostate. critical analysis of two different test populations. Urology 53: (1999) 736-745
61. Wu J.T., and Liu G.H. Advantages of replacing the total PSA assay with the assay for PSA-alpha-1-antichymotrypsin complex for the screening and management of prostate cancer. J Clin Lab Anal 12: (1998) 32-40